APA (7th ed.) Citation

Fox, L., Egeler, M., Singer, S., Brédart, A., Kiyota, N., Saad, A., . . . Van Hemelrijck, M. (2025). 3191eP Development of an EORTC strategy to measure health-related quality of life in cancer patients receiving immune checkpoint inhibitors: Phase I and II. Annals of Oncology, 36, S695. https://doi.org/10.1016/j.annonc.2025.08.1662

Chicago Style (17th ed.) Citation

Fox, L., et al. "3191eP Development of an EORTC Strategy to Measure Health-related Quality of Life in Cancer Patients Receiving Immune Checkpoint Inhibitors: Phase I and II." Annals of Oncology 36 (2025): S695. https://doi.org/10.1016/j.annonc.2025.08.1662.

MLA (9th ed.) Citation

Fox, L., et al. "3191eP Development of an EORTC Strategy to Measure Health-related Quality of Life in Cancer Patients Receiving Immune Checkpoint Inhibitors: Phase I and II." Annals of Oncology, vol. 36, 2025, p. S695, https://doi.org/10.1016/j.annonc.2025.08.1662.